Nan Fung Trinity HK Ltd. Acquires 25,975 Shares of Celcuity, Inc. $CELC

Nan Fung Trinity HK Ltd. increased its holdings in shares of Celcuity, Inc. (NASDAQ:CELC) by 33.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 103,775 shares of the company’s stock after buying an additional 25,975 shares during the quarter. Nan Fung Trinity HK Ltd.’s holdings in Celcuity were worth $8,252,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in CELC. PNC Financial Services Group Inc. grew its holdings in Celcuity by 20.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock valued at $59,000 after buying an additional 86 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of Celcuity by 15.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 944 shares of the company’s stock valued at $99,000 after acquiring an additional 124 shares during the last quarter. Integrity Alliance LLC. lifted its holdings in shares of Celcuity by 2.2% during the 3rd quarter. Integrity Alliance LLC. now owns 11,868 shares of the company’s stock worth $944,000 after acquiring an additional 250 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Celcuity by 1.0% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 31,092 shares of the company’s stock worth $3,253,000 after acquiring an additional 297 shares during the period. Finally, IFP Advisors Inc lifted its holdings in shares of Celcuity by 42.6% during the 3rd quarter. IFP Advisors Inc now owns 995 shares of the company’s stock worth $79,000 after acquiring an additional 297 shares during the period. 63.33% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CELC has been the topic of several research analyst reports. Wall Street Zen cut shares of Celcuity from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. TD Cowen reaffirmed a “buy” rating and set a $145.00 price target on shares of Celcuity in a research report on Wednesday, October 21st. HC Wainwright cut their price target on shares of Celcuity from $155.00 to $150.00 and set a “buy” rating on the stock in a research note on Monday. Zacks Research lowered shares of Celcuity from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 13th. Finally, Stifel Nicolaus decreased their price target on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $151.79.

Celcuity Price Performance

Shares of NASDAQ:CELC opened at $64.17 on Friday. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 14.62. The business has a 50-day moving average of $73.11 and a two-hundred day moving average of $98.49. Celcuity, Inc. has a 12 month low of $53.54 and a 12 month high of $151.02.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, November 5th. The company reported ($1.21) EPS for the quarter, topping analysts’ consensus estimates of ($1.51) by $0.30. On average, analysts anticipate that Celcuity, Inc. will post -5.01 earnings per share for the current fiscal year.

About Celcuity

Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.